Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Status:
RECRUITING
Trial end date:
2032-07-31
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).